Hearing loss linked to accelerated Alzheimer’s progression via GDF1 pathway

FHS
March 20, 2024
11:42 pm

Study unveils the GDF1 signaling pathway’s role in mitigating the adverse effects of hearing loss on Alzheimer’s disease, spotlighting potential avenues for therapeutic development.

‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar

Regeneron might be ready for competition with its blockbuster drug Eylea, but it’s not clear that investors are. On Thursday morning, the biotech’s leadership fielded

November 1, 2024

Quibim introduces QP-Liver for enhancing liver disease diagnosis through MRI analysis

Quibim, a global company pioneering imaging biomarkers for precision medicine, is today announcing the launch of a new product, QP-Liver, which improves the diagnosis of

March 24, 2024

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.